Business Wire (Thu, 8:01AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,467 people get STJ articles and Market Currents by email alert.
Get email alerts on STJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (May 8, 2013)
-
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
-
Business Wire (Apr 17, 2013)
-
Business Wire (Apr 4, 2013)
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26 -
Business Wire (Mar 21, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Boston Scientific Could Benefit From St. Jude Medical's TroublesTrefis • Tue, Nov 27, 2012 -
-
-
Why St. Jude Is Poised To Become A Solid Income StockValuentum • Thu, Sep 20, 2012 -
St. Jude Medical's Weaker Guidance Presents Another OpportunityStephen Simpson • Wed, Jul 18, 2012
-
-
-
-
-
-
St. Jude Medical: Earnings PreviewZacks Investment Research • Wed, Jan 25, 2012
-
Quality, With A Dividend, Now On Sale: St. Jude MedicalK202 • Tue, Jan 10, 2012 -
St. Jude Remains On Our Dividend Growth Watch ListValuentum • Wed, Jan 4, 2012
-
-
St. Jude: Earnings PreviewZacks Investment Research • Wed, Oct 19, 2011
-
-
-
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26
-
-
-
-
-
-
Fortune Could Favor A Bolder TerumoStephen Simpson • Thu, Feb 21
-
-
-
-
-
-
-
-
Checking The Pulse Of Healthcare StocksStock Traders Daily • Tue, Jan 22
-
-
-
St. Jude Medical Inc. - Analyst/Investor DayFri, Feb 3, 2012
-
St. Jude Medical Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
St. Jude Medical Inc. Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
St. Jude Medical Inc. Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
St. Jude Medical Inc., Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
St. Jude Medical, Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
St. Jude Medical, Inc. Q1 2009 Earnings Call TranscriptWed, Apr 22, 2009 • 1 Comment
-
St. Jude Medical Inc. Q4 2008 Earnings Call TranscriptTue, Jan 27, 2009
-
Business Wire (May 8, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 17, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 9, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Mar 21, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Feb 27, 2013)
-
at Fox Business (Feb 25, 2013)
STJ vs. ETF Alternatives
Company Description
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. Our four operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, March 8, 2:55 PM St. Jude Medical (STJ +1.1%) is up today after the company reports the first patient implant in a new trial evaluating the company's Aplatzer Cardiac Plug, a device for the prevention of stroke. The trial is designed to determine if the device is safe and effective in preventing thrombus from migrating out of the left atrial appendage in patients with non-valvular atrial fibrillation who have a high risk for stroke. Comment! [Healthcare, On the Move]
- Friday, February 15, 2:10 PM St. Jude Medical (STJ -3.4%) has been working overtime to convince the Street that its Durata heart device leads are safe, but Cowen doesn't take the bait, downgrading the stock to Market Underperform over concerns that the new heart wire is no different from the ones already taken off the market. The firm cites a "significant risk" of a recall, which would " meaningfully damage" its defibrillator and pacemaker business. Comment! [Healthcare, On the Move]
- Tuesday, January 15, 2:22 PM Boston Scientific (BSX +2.5%) hits a 16-month high today after Credit Suisse upped the stock to Outperform, citing a better top-line and improved visibility. On those catalysts, the firm reduces the valuation discount it thinks the stock should trade at versus rivals St. Jude (STJ) and Medtronic (MDT) to 10%. The stock currently trades at around a 20% discount to its peers. Comment! [Healthcare, On the Move]
- Friday, November 30, 2012, 11:27 AM St. Jude Medical (STJ +1.4%) gains on the back of yesterday's $1B buyback announcement and an upgrade to Buy at Mizuho. The firm says that concerns about a Durata recall are overblown, and that any impact on its EPS from market share loss in implanted defibrillators should be "more than offset" by yesterday's buyback announcement. Comment! [Healthcare, On the Move]
- Monday, November 26, 2012, 11:01 AM Boston Scientific (BSX +2.7%) bucks a down tape this morning on an upgrade to Buy at Citigroup. The firm says BSX is positioned to be the biggest winner from St. Jude Medical's (STJ -1%) Durata troubles. Citi expects it will be taken off the market within six months, and the ripple effects are likely to cost STJ around $820M in annual sales. BSX could easily take 41% of that market share, with Medtronic (MDT -0.9%) absorbing around 29%. Citi's upgrade differs widely from comments made on Friday by BofA Merrill, which put the risk of a Durata recall well below 50%. Comment! [Healthcare, On the Move]
- Friday, November 23, 2012, 11:50 AM Shares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday following the FDA's release of a report citing serious flaws in STJ's oversight of Durata. BofA Merrill Lynch notes that the report found no new safety issues and the probability of a recall stands well below 50%, which is already priced into the stock. It reiterates a Buy with a potential downside to $24 and an upside peaking around $40. Comment! [Healthcare, On the Move]
- Wednesday, November 21, 2012, 12:45 PM Midday top 10 gainers: MEMS +72%. NLP +38%. ARCI +20%. INFI +14%. VVUS +14%. NCTY +13%. SKX +12%. SQNM +11%. PSUN +11%. MTSL +11%. Midday top 10 Losers: STV -46%. ZLC -29%. CNET -18%. SCHL -18%. TLYS -17%. STJ -14%. CLNT -13%. EBR -11%. HGSH -11%. KID -11%. 1 Comment [On the Move]
- Monday, November 19, 2012, 2:23 PM St. Jude Medical (STJ +2%) says its received European approval for its Portico heart valve replacement device. The approval gives STJ access to a burgeoning market for the devices, and the news gives a much-needed lift to the stock after a string of negative headlines in recent months has driven the stock down near 52-week lows. Since October alone, STJ has shaved nearly 17% off its market cap. Comment! [Healthcare, On the Move]
- Wednesday, October 17, 2012, 9:33 AM St. Jude Medical (STJ -6%) could receive a warning letter from the FDA about its manufacturing facility in Sylmar, California, where it produces defibrillators and pacemakers and which the FDA is inspecting. The news, which CEO Dan Starks disclosed on an earnings call, is not a surprise given the massive insulation problems St. Jude has had with the wires for its defibrillators. 1 Comment [Healthcare, On the Move]
-
Wednesday, October 17, 2012, 9:10 AM
Premarket gainers: CYMI +63%. CREE +10%. FSLR +6%.
Losers: FTNT -17%. APOL -12%. STJ -6%. CHKP -5%. Comment! [On the Move] - Wednesday, October 17, 2012, 8:14 AM More on St. Jude Medical (STJ) Q3: net profit drops to $176M from $227M, due to charges of $80M that are mostly related to restructuring. Outlook: Q4 EPS of $0.86-$0.88 vs. consensus of $0.89. FY EPS of $3.42-$3.44 vs. consensus of $3.43 and prior guidance of $3.40-$3.45. Board authorizes $300M repurchase program. Shares -3.6%. Comment! [Earnings, Healthcare, On the Move]
- Thursday, August 16, 2012, 2:34 PM St. Jude Medical (STJ -3.5%) drops after the FDA orders a review of its Riata defibrillator leads. The agency recommends patients who have defibrillators with Riata leads should have x-rays or other imaging scans to check for abnormalities in the insulation surrounding the lead. STJ recalled the leads back in Nov. 2011; FDA says routine imaging may detect previously unrecognized abnormalities. Comment! [Healthcare, On the Move]
- Thursday, June 28, 2012, 11:32 AM The Supreme Court opinion on the Healthcare Act means that medical device makers still face a 2.3% tax on domestic sales starting next year unless they can persuade Congress to repeal it. Shares are sliding: MDT -1.2%, BSX -2.7%, STJ -1%, EW 1.1%, SYK -1.9%, ATRC -4.7%, CYBX -1.6%. 1 Comment [Healthcare, On the Move]
- Friday, June 22, 2012, 4:11 PM St. Jude Medical (STJ +2.6%) jumps at the close after a last-minute release of comments on a database report suggesting a single Durata defibrillation lead was damaged by external abrasion - different from the inside-out abrasion seen previously on Riata leads. (previously) Comment! [Healthcare, On the Move]
- Monday, June 18, 2012, 1:10 PM Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata defibrillator cable. A report turned up in an FDA database and was said to be due to a fraying issue, prompting fears that problems with STJ's earlier Riata product may not be isolated. But anyone can file to that database, Lazard says, and the cable wasn't returned to STJ for analysis. 3 Comments [Healthcare, On the Move]
- Tuesday, June 12, 2012, 12:44 PM St. Jude Medical (STJ -5.5%) shares plunge suddenly on a report that the company's Durata defribilator is linked to a cable defect. STJ has had a similar problem with its Riata lead, which is no longer on the market; the company has said Durata leads, which it still sells, don't have the problem because they use a different type of insulation material. Comment! [Healthcare, On the Move]
-
Alan Brochstein
$STJ has had a nice run, but it's still a bit cheap to the peers despite better growth potential - View all 0 replies
-
Alan Brochstein
$STJ reacted well to an independent report that its Durata leads don't have the alleged problems that some suggest - stock is cheap at 12 PE - View all 1 replies
-
WallStreetDebunker: There are many stocks in the medical devices sector with low valuations and good demographic trends ahead. Definitely good hunting grounds.
-
- View all 0 replies
-
Alan Brochstein
$EW pounded on miss and lower guidance - not bad at 70, could be a buy at 68 (but I prefer $STJ) - View all 0 replies
-
Alan Brochstein
$STJ sales reduction mainly due to stronger dollar but distributed products in Japan are under pressure too - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 5 replies
-
-
Alan Brochstein: $RMD is good stuff - it's on my watchlist and one of my clients owns a lot. At this point, it's a hold
-
Alan Brochstein
$STJ had a nice outlook - conservative yet delivering EPS above expectations. Raising my target to 60 - View all 0 replies
LATEST REPLIES
-
Alan Brochstein
$STJ reacted well to an independent report that its Durata leads don't have the alleged problems that some suggest - stock is cheap at 12 PE - View all 1 replies
-
WallStreetDebunker: There are many stocks in the medical devices sector with low valuations and good demographic trends ahead. Definitely good hunting grounds.
-
- View all 5 replies
-
-
Alan Brochstein: $RMD is good stuff - it's on my watchlist and one of my clients owns a lot. At this point, it's a hold
-
- View all 1 replies
-
-
- View all 8 replies
-
-
Jeremy Johnson: STJ is not expensive, but it is getting close to fair value. Fair value stocks are still good to own... fair equity return is 8% a year.
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
jason2788: go denver is right, i skipped around my house like a little school girl.
-
Alan Brochstein
Lots of pain in med devices - STJ and ZMH stand out to me for near-term reversal potential - View all 3 replies
-
Alan Brochstein: The CardioMEMS panel ruling has an immaterial impact on near-term financials, though it is disappointing.
-
Ocean Man: Minor bad news that hits harder than it should = stocks on sale.
-
fmhaynes11
Did STJ deserve the hit caused by FDA ruling on CardioMEMS heart implant device ? Is STJ that reliant on that technology ? - View all 1 replies
-